
    
      This is an open label, dose escalation study to determine the maximum tolerated dose (MTD) of
      pazopanib combined with weekly paclitaxel and carboplatin in patients with advanced solid
      tumors. There will be a dose expansion cohort of thirty patients to assess detailed
      pharmacokinetics and to assess any signal of activity in patients with solid tumors and in a
      portion who have breast cancer that is triple negative (ER-negative, PR-negative, and
      HER2-negative).
    
  